A Study of TAK-105 in Healthy Adults

Exclusion Criteria

• •1. Participated in another investigational study within 4 weeks (or based on local regulations) or within 5 half-lives of the investigational product before the screening visit. The 4-week or 5 half-lives window will be derived from the date of the last dose and/or adverse event (AE) related to the study procedure in the previous study to the screening visit of the current study.
• •2. Has a history of significant multiple and/or severe allergies (example, food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
• •3. Has a known hypersensitivity or contraindication to any component of TAK 105.
• •4. Has positive pregnancy test or is lactating or breastfeeding.
• •5. Has known or suspected current coronavirus disease 2019 (COVID-19) infection or is at risk of COVID-19 infection as assessed by the investigator.
• •6. Unable to refrain from or anticipates using all medications including herbal medicines beginning approximately 7 days before administration of the first dose of study drug, throughout the study until the last follow-up visit.
• •7. With history or presence of:
• •* 3 or more incidences of syncope (example, vasovagal) within the last 5 years prior to screening;
• •* A family history of unexplained sudden death or channelopathy;
• •* Brugada syndrome (RBBB \[right bundle branch block\] pattern with ST-elevation in leads V1 V3);
• •* CV or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, stroke, sick sinus syndrome, pulmonary congestion, symptomatic or significant cardiac arrhythmia, supraventricular or ventricular tachycardia, second-degree atrioventricular (AV) block type 2, third degree AV block, prolonged QT interval with Fridericia correction method (QTcF) interval, hypokalemia, hypomagnesemia, or conduction abnormalities;
• •* Risk factors for Torsade de Pointes (example, heart failure, cardiomyopathy, or family history of Long QT Syndrome);
• •* Any clinically significant ECG findings or medical history including: long or short QTcF (over 450 milli second \[msec\] or less than 360 msec), bifascicular block or QRS greater than equal to (\>=)120 msec or PR interval \> 200 msec at screening or Day 1 pre-Hour 0;
• •* Has a documented history of sinus bradycardia less than (\<) 45 beats per minute \[bpm\]) based upon vital signs assessments, sinoatrial block as evidenced on ECG or sinus pause \>=3 seconds on ECG or predose telemetry.
• •8. Has an average semi recumbent blood pressure (BP) less than 90 (systolic) and 60 (diastolic) millimeter of mercury (mmHg) or greater than 140/90 mmHg from screening to predose, inclusive.
• •9. From screening to Day -2, participants with an average semirecumbent heart rate (HR) \<55 or \>100 beats per minute (bpm) should be excluded. From Day -2 to predose, enrollment of participants with an average HR \<55 or \>100 bpm will be left to the judgment of the investigator, unless HR is \<50 bpm, which must be discussed with the medical monitor for approval.
• •10. Has orthostatic hypotension defined as a decrease in systolic BP (SBP) \>=20 mmHg or a decrease in diastolic BP (DPB) \>=10 mmHg at approximately 2 minutes of standing when compared with BP from the semirecumbent position at screening to predose assessments, inclusive.
• •11. Has postural orthostatic tachycardia, defined as an increase of \>30 bpm or HR \>120 bpm at approximately 2 minutes of standing, at screening to predose assessments, inclusive.